Acetyl-L-Carnitine


Endogenous acetylated amino acid derivative and mitochondrial metabolic cofactor with cholinergic, neurotrophic, and epigenetic activity

An acetylated derivative of L-carnitine that serves as a mitochondrial shuttle for acetyl groups, a precursor to the neurotransmitter acetylcholine, and an epigenetic modulator of NF-kappaB-dependent gene expression, studied across peripheral neuropathy, major depressive disorder, cognitive decline, and age-related mitochondrial dysfunction.

Abstract

Acetyl-L-carnitine (ALCAR, ALC, levacecarnine), the acetyl ester of the endogenous quaternary ammonium compound L-carnitine, is a naturally occurring metabolic intermediate synthesized intramitochondrially by carnitine acetyltransferase in essentially all human tissues including brain, liver, heart, kidney, and skeletal muscle. The compound occupies a unique pharmacological position as both an endogenous metabolite with defined physiological roles in mitochondrial energy metabolism and a supplemental or therapeutic agent with a clinical evidence base spanning peripheral neuropathy, major depressive disorder, mild cognitive impairment, Alzheimer disease, and age-related mitochondrial dysfunction. Unlike L-carnitine itself, the acetylated form crosses the blood-brain barrier with substantially greater efficiency and serves as a direct donor of acetyl groups for the synthesis of acetylcholine through the coupled activity of carnitine acetyltransferase and choline acetyltransferase in cholinergic neurons, a property that underwrites much of its central nervous system pharmacology. The molecular pharmacology of ALCAR extends beyond the classical mitochondrial shuttle function. The compound acts as an epigenetic modulator through acetylation of the p65/RelA subunit of the NF-kappaB transcription factor and of histones H3 and H4, leading to upregulation of type 2 metabotropic glutamate (mGlu2) receptor expression at nerve terminals and producing a mechanistically distinct analgesic effect that is not shared by non-acetylated L-carnitine. This epigenetic mechanism, first characterized in models of chronic neuropathic pain, is the molecular basis for the sustained analgesic activity observed in clinical neuropathy trials. ALCAR additionally increases the synthesis and utilization of nerve growth factor (NGF) in the central and peripheral nervous system and promotes peripheral nerve fiber regeneration, properties demonstrated in both aged-animal models and in clinical sural nerve morphometry. The clinical evidence base is substantial. A systematic review and meta-analysis of randomized controlled trials in peripheral neuropathic pain confirmed significant pain reduction across diabetic, HIV-associated antiretroviral toxic, and chemotherapy-induced neuropathy subtypes. In major depressive disorder, a 2018 meta-analysis of 12 randomized controlled trials (total 791 participants) reported ALCAR supplementation to be significantly superior to placebo and comparably effective to established antidepressants (fluoxetine, amisulpride) with substantially fewer adverse events. A contemporaneous cross-sectional biomarker study identified plasma ALCAR deficiency as a correlate of major depressive disorder severity and earlier age of onset. In mild cognitive impairment and early Alzheimer disease, a meta-analysis of double-blind randomized controlled trials reported a significant advantage for ALCAR over placebo on clinical global impression scales and psychometric testing, though effect sizes were modest and a Cochrane review in the same period concluded that the evidence was insufficient to recommend clinical use. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph